Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …

Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …

Background Survival is poor among patients with triple-class–exposed relapsed and
refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed …

We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …

Background The molecular determinants of clinical responses to decitabine therapy in
patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. …

Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the
treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 …

We studied adults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8
HLA-matched unrelated donor (n = 1982) transplantation. Haploidentical recipients received …

Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, …

The sensitivity of massively-parallel sequencing has confirmed that most cancers are
oligoclonal, with subpopulations of neoplastic cells harboring distinct mutations. A fine resolution …

This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed
CRd—carfilzomib (20, 27, or 36 mg/m 2 , days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), …